CJC-1295 DAC: Extended-Release GHRH Analogue
A comprehensive guide to CJC-1295 with Drug Affinity Complex (DAC), a long-acting GHRH analogue with a half-life of 6-8 days, studied for its ability to sustain elevated IGF-1 and growth hormone levels.
Introduction
CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analogue engineered for extended half-life. The Drug Affinity Complex (DAC) binds to serum albumin, extending the half-life from minutes to 6-8 days.
Chemical Profile
- Sequence: Modified GHRH(1-29) with DAC moiety
- CAS Number: 863288-34-0 (with DAC)
- Molecular Weight: ~3,647.2 g/mol
- Appearance: White lyophilized powder
CJC-1295 With DAC vs Without DAC
| Parameter | With DAC | Without DAC (GRF 1-29) |
|---|---|---|
| Half-life | 6-8 days | 30 minutes |
| Dosing frequency | Weekly | 2-3x daily |
| IGF-1 elevation | Sustained | Pulsatile |
| Albumin binding | Yes | No |
Mechanism of Action
CJC-1295 acts on GHRH receptors in the anterior pituitary, stimulating natural GH release. The DAC moiety (lysine linker + adduct) covalently binds to serum albumin, preventing rapid renal clearance.
Synergy with GHRPs
CJC-1295 + a GHRP (Ipamorelin, GHRP-2, or GHRP-6) produces a synergistic GH pulse greater than the sum of either alone:
- CJC-1295 acts on GHRH receptors
- GHRPs act on GHS-R1a (ghrelin) receptors
- Different pathways amplify GH release
Analytical Specifications
| Parameter | Specification |
|---|---|
| Purity | >= 98% (HPLC) |
| Identity | MS confirmed |
| Peptide content | >= 85% |
Storage
- Lyophilized: -20C, 2-5 years
- Reconstituted: 4C, 30 days
Conclusion
CJC-1295 with DAC is a valuable research tool for sustained GH pathway studies. All products for in vitro research use only.